Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol + glycopyrronium versus glycopyrronium alone in moderate COPD
RBR-7k576jPhase 4Not yet recruiting
- Sponsor
- Hospital de Clínicas da Universidade Federal do Paraná
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of glycopyrronium and indacaterol in chronic obstructive pulmonary disease (COPD) and emphysema (2 arms), sponsored by Hospital de Clínicas da Universidade Federal do Paraná. Primary endpoint: Pulmonary function. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
glycopyrroniumindacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)emphysema
Beyond the preview
Go deeper on RBR-7k576j.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7k576j.